ArticleScience signaling2017
Generation of specific inhibitors of SUMO-1- and SUMO-2/3-mediated protein-protein interactions using Affimer (Adhiron) technology.
Article in Science signaling, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 50 citations in OpenAlex.
- Non-covalent SUMO interactions with ligases and effectors: SUMO-interacting motifs and beyond.Essays in biochemistry · 2025Review
- SUMO2/3 conjugation of TDP-43 protects against aggregation.Science advances · 2025Article
- Use of Affimer technology for inhibition of α2-antiplasmin and enhancement of fibrinolysis.Blood advances · 2025Article
- Affimer reagents as tool molecules to modulate platelet GPVI-ligand interactions and specifically bind GPVI dimer.Blood advances · 2024Article
- Interplay between PML NBs and HIRA for H3.3 dynamics following type I interferon stimulus.eLife · 2023Article
- MD Simulation Reveals Regulation of Mechanical Force and Extracellular Domain 2 on Binding of DNAM-1 to CD155.Molecules (Basel, Switzerland) · 2023Article
- Labeling of a mutant estrogen receptor with an Affimer in a breast cancer cell line.Biophysical journal · 2022Article
- SUMO Interacting Motifs: Structure and Function.Cells · 2021Review
- RAS-inhibiting biologics identify and probe druggable pockets including an SII-α3 allosteric site.Nature communications · 2021Article
- POLArIS, a versatile probe for molecular orientation, revealed actin filaments associated with microtubule asters in early embryos.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Natural product-informed exploration of chemical space to enable bioactive molecular discovery.RSC medicinal chemistry · 2021Review
- The SUMO pathway in pancreatic cancer: insights and inhibition.British journal of cancer · 2021Review
- Selection and characterisation of Affimers specific for CEA recognition.Scientific reports · 2021Article
- Selective Affimers Recognise the BCL-2 Family Proteins BCL-xChembiochem : a European journal of chemical biology · 2021Article
- Exploiting nanobodies and Affimers for superresolution imaging in light microscopy.Molecular biology of the cell · 2019Article
- Advances in targeted degradation of endogenous proteins.Cellular and molecular life sciences : CMLS · 2019Review
- Studies of the oligomerisation mechanism of a cystatin-based engineered protein scaffold.Scientific reports · 2019Article
- Article
- Visualizing ubiquitination in mammalian cells.EMBO reports · 2019Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 2 countries.
Funding
Abstract
Because protein-protein interactions underpin most biological processes, developing tools that target them to understand their function or to inform the development of therapeutics is an important task. SUMOylation is the posttranslational covalent attachment of proteins in the SUMO family (SUMO-1, SUMO-2, or SUMO-3), and it regulates numerous cellular pathways. SUMOylated proteins are recognized by proteins with SUMO-interaction motifs (SIMs) that facilitate noncovalent interactions with SUMO. We describe the use of the Affimer system of peptide display for the rapid isolation of synthetic binding proteins that inhibit SUMO-dependent protein-protein interactions mediated by SIMs both in vitro and in cells. Crucially, these synthetic proteins did not prevent SUMO conjugation either in vitro or in cell-based systems, enabling the specific analysis of SUMO-mediated protein-protein interactions. Furthermore, through structural analysis and molecular modeling, we explored the molecular mechanisms that may underlie their specificity in interfering with either SUMO-1-mediated interactions or interactions mediated by either SUMO-2 or SUMO-3. Not only will these reagents enable investigation of the biological roles of SUMOylation, but the Affimer technology used to generate these synthetic binding proteins could also be exploited to design or validate reagents or therapeutics that target other protein-protein interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.